Ultimele actualizari :
28/04/2024
Citostatic   Trastuzumab  
Injectabil
Stabilitatea in solutie Stabilitatea in amestec Factorii care influenteaza stabilitatea Compatibilitate Microunde Bibliografie Pdf

Denumirea comerciala   Denumirea comerciala     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Herceptin Arabia Saudita, Argentina, Australia, Austria, Belgia, Brazilia, Canada, Chilli, Columbia, Danemarca, Ecuador, Egipt, Elvetia, Emiratele Arabe Unite, Finlanda, Franta, Germania, Grecia, Iran, Irlanda, Islanda, Italia, Japonia, Luxemburg, Malaezia, Marea Britanie, Maroc, Mexic, Norvegia, Noua Zeelandă, Olanda, Peru, Polonia, Portugalia, Romania, Spania, SUA, Suedia, Turcia, Ungaria
Herclon Peru
Hertraz Chilli
Herzuma Belgia, Franta, Germania, Marea Britanie, Spania, SUA
Kanjinti Belgia, Germania, Marea Britanie, Spania
Trastuzumab Baxter Noua Zeelandă
Trazimera Marea Britanie
Bibliografie   Injectabil   Bibliografie : Trastuzumab  
Tip Publicare
2296 Laborator Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
2975 Poster Nalenz H, Schoenhammer K, Dietel E, Heynen S.R, Grauschopf U, Mahler H.C.
In-Use stability of herceptin for subcutaneous injection with different administration materials.
ESCP 2014 2014
3077 Laborator Trastuzumab (Herceptin®) – Summary of Product Characteristics
Roche 2019
3113 Carte Herceptin
Compendium Suisse des m?dicaments 2010
3258 Ziar Kaiser J, Krämer I.
Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags.
Int J Pharm Compound 2011 ; 15, 6 : 515-520.
3343 Poster Vieillard V, da Silva R, Astier A, Paul M.
Physicochemical stability of diluted trastuzumab solutions stored 6 months at 4°C.
ECOP Congress, Budapest, Hungary 2012
3366 Ziar Kwong Glover Z.W, Gennaro L, Yadav S, Demeule B, Wong P.Y, Sreedhara A.
Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration.
J Pharm Sci 2012 ; DOI 10.1002 / jps.23403
3386 Ziar Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A.
Long-term physico-chemical stability of diluted trastuzumab.
Int J Pharm 2013 ; 448: 101-104.
3647 Laborator Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics
Roche 2019
3849 Ziar Pabari R.M, Ryan B, Ahmad W, Ramtoola Z.
Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions.
Curr Pharm Biotech 2013 ; 14, 2: 220-225.
4163 Ziar Nalenz H, K?pf E, Dietel E.
Prolonged In-Use Stability of Reconstituted Herceptin in Commercial Intravenous Bags.
Int J Pharm Compound 2018 22;5:417-423
4191 Ziar Vieillard V, Astier A, Paul M.
Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at varioustemperatures.
GaBI Journal 2018
4194 Ziar Kim S.J, Lee J.W, Kang H.Y, Kim S.Y, Shin Y.K, Kim K.W, Oh J.S, Lim K.J, Kim J.Y.
In-Use Physichochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion.
Bio Drugs 2018 32;619-625
4271 Ziar Yun J, Kim J, Chung J, Hwang S-J, Park S-J.
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Adv Ther 2019
4396 Ziar Lueras A, Polozova A, Asbury D, Hippenmeyer J, Litowski J, Goss M, Breslin P, Crampton S.
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions.
GaBI Journal 2020 ; 9, 1:
4477 Ziar Crampton S, Polozoxa A, Asbury D, Lueras A, Breslin P, Hippenmeyer J, Litkowski J,,Goss M.
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions.
GaBI Journal 2020 ; 9, 1: 5-13.
4493 Ziar Le Guyader G, Vieillard V, Paul M.
Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
J Oncol Pharm Practice 2020
4649 Ziar Davies L, Milligan K, Corris M, Clarke I, Dwyer P, Lee S-E, Teraoka J, Crouse-Zeineddini J, Hippenmeyer J.
Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices.
GaBI Journal 2021 ; 10, 4
4754 Ziar Weiser S, Burns C, Zartler E
Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions.
J Oncol Pharm Practice 2023 ;29,3:

  Mentions Légales